| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | August 16, 2023 |
| Accession Number: | 0001193125-23-210812 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/8/2023 | $42.00 | Outperform → Neutral | Wedbush |
| 3/6/2023 | $41.00 | Overweight | Piper Sandler |
| 3/1/2023 | $43.00 | Buy | Guggenheim |
| 12/5/2022 | $30.00 | Overweight | Wells Fargo |
| 6/28/2022 | $30.00 | Buy | Stifel |
15-12G - CHINOOK THERAPEUTICS, INC. (0001435049) (Filer)
EFFECT - CHINOOK THERAPEUTICS, INC. (0001435049) (Filer)
S-8 POS - CHINOOK THERAPEUTICS, INC. (0001435049) (Filer)
SC 13D/A - CHINOOK THERAPEUTICS, INC. (0001435049) (Subject)
SC 13D - CHINOOK THERAPEUTICS, INC. (0001435049) (Subject)
SC 13G/A - CHINOOK THERAPEUTICS, INC. (0001435049) (Subject)
SEATTLE, July 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient with IgA nephropathy (IgAN) has been enrolled in the BEYOND study, a pivotal phase 3 clinical trial evaluating the safety and efficacy of zigakibart (BION-1301), a potentially disease-modifying anti-APRIL monoclonal antibody. "Initiation of the phase 3 BEYOND study is an important step towards our goal of providing an innovative treatment option for patients with IgAN, a disease with high unmet need and limited treatment options," said E
NEW YORK, June 24, 2023 (GLOBE NEWSWIRE) -- Bunge Limited (NYSE:BG) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of BG and Viterra Limited. Under the terms of the agreement, Viterra Limited shareholders will receive approximately 65.6 million shares of BG common stock and $2.0 billion in cash. In addition, BG will assume $9.8 billion of Viterra Limited debt and BG plans to repurchase $2.0 billion of BG common stock. If you are a BG investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-m
CHK-336 was generally well tolerated in healthy volunteers (HV) who received single doses up to 500 mg and multiple doses up to 60 mg for 14 daysPharmacokinetics (PK) was well characterized with dose-proportional exposures and a half-life that supports once-daily dosingSuccessful implementation of a novel 13C2-glycolate tracer established proof-of-mechanism of CHK-336 to block hepatic oxalate production in HVsOne serious adverse event (SAE) of anaphylaxis occurred in a multiple ascending dose HV who received one 125 mg dose CHK-336, resulting in voluntary study pauseAdditional research presented on the impact of maladaptive tubular epithelial cells on progression of chronic kidney disease S
4 - CHINOOK THERAPEUTICS, INC. (0001435049) (Issuer)
4 - CHINOOK THERAPEUTICS, INC. (0001435049) (Issuer)
4 - CHINOOK THERAPEUTICS, INC. (0001435049) (Issuer)
SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today reported financial results for the first quarter ended March 31, 2023 and provided corporate updates. "During the first quarter of 2023, we continued to advance our pipeline of clinical and preclinical programs for rare, severe chronic kidney diseases. We recently completed full enrollment of the phase 3 ALIGN clinical trial, are on track to initiate the phase 3 BION-1301 IgAN clinical trial mid-year and expect to report topline ALIGN results in the fourth quarter of thi
SEATTLE, April 13, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Robert W. Azelby to its Board of Directors. Mr. Azelby brings more than 20 years of executive leadership and commercial experience in the biopharmaceutical industry to Chinook. "We are thrilled to welcome Bob to Chinook's board of directors as we advance our pipeline through key milestones in 2023 and beyond," said Eric Dobmeier, president and chief executive officer of Chinook Therapeutics. "Bob brings significant industry experience in bu
SEATTLE, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Andrew Oxtoby as chief commercial officer. "We are pleased to welcome Andrew to Chinook as we prepare for a year of important milestones for our atrasentan and BION-1301 programs," said Eric Dobmeier, president and chief executive officer of Chinook Therapeutics. "Andrew is an accomplished industry leader with more than 20 years of global biopharmaceutical experience and a proven track record of building commercial strategies and executing n
Zigakibart treatment continues to demonstrate rapid and sustained reductions in mechanistic biomarkers, including IgA and Gd-IgA1 levels, which correspond to clinically meaningful proteinuria reductions in patients with IgAN across Cohorts 1 and 2Zigakibart is well-tolerated, with no ADAs observed or treatment discontinuations due to adverse events (AEs) in patients with IgAN across Cohorts 1 and 2 In all patients combined from both Cohorts 1 and 2, zigakibart demonstrated mean proteinuria reductions of 20% at 12 weeks of treatment, 39% at 24 weeks of treatment and 67% at 52 weeks of treatmentExtended treatment with zigakibart resulted in sustained clinical benefit, with 67% mean proteinuria
Updated interim data to be presented from Cohort 1 and 2 of the ongoing phase 1/2 study of BION-1301 in patients with IgANInitial data to be presented from the phase 1 study of CHK-336 in healthy volunteersAdditional presentations on the design of the phase 2 ASSIST study for atrasentan in patients with IgAN on background RASi and SGLT2i and the phase 3 BEYOND study of BION-1301 in patients with IgAN, as well as research on the impact of maladaptive tubular epithelial cells on disease progression in chronic kidney diseasesChinook to host investor conference call and webcast on June 16, 2023 at 8:15 am EDT to review and discuss the presentations and provide corporate updates SEATTLE, May 05
The initial response to de novo subcutaneous (SC) BION-1301 treatment in Cohort 2 is highly consistent with Cohort 1 across both mechanistic biomarkers and proteinuria reductionsBION-1301 is well-tolerated, with no serious adverse events (SAEs) and no treatment discontinuations due to adverse events (AEs) in patients with IgAN across Cohorts 1 and 2BION-1301 continues to demonstrate rapid and sustained reductions in mechanistic biomarkers, including IgA and Gd-IgA1 levels, in patients with IgAN across Cohorts 1 and 2In Cohort 1, BION-1301 demonstrated mean proteinuria reductions of 30.4% at 12 weeks of treatment, 48.8% at 24 weeks of treatment and 66.9% at 52 weeks of treatment, as well as 6
Upgrades JP Morgan upgraded the previous rating for Telephone and Data Systems Inc (NYSE:TDS) from Neutral to Overweight. For the second quarter, Telephone and Data had an EPS of $0.17, compared to year-ago quarter EPS of $0.15. The stock has a 52-week-high of $17.41 and a 52-week-low of $6.43. At the end of the last trading period, Telephone and Data closed at $13.20. JP Morgan upgraded the previous rating for United States Cellular Corp (NYSE:USM) from Neutral to Overweight. United States Cellular earned $0.05 in the second quarter, compared to $0.25 in the year-ago quarter. At the moment, the stock has a 52-week-high of $35.00 and a 52-week-low of $13.79. United States Cellular closed
Wedbush analyst Laura Chico downgrades Chinook Therapeutics (NASDAQ:KDNY) from Outperform to Neutral and announces $42 price target.
Upgrades According to Northcoast Research, the prior rating for Boeing Co (NYSE:BA) was changed from Sell to Neutral. In the second quarter, Boeing showed an EPS of $0.82, compared to $0.37 from the year-ago quarter. At the moment, the stock has a 52-week-high of $240.13 and a 52-week-low of $120.99. Boeing closed at $238.85 at the end of the last trading period. For Varonis Systems Inc (NASDAQ:VRNS), Craig-Hallum upgraded the previous rating of Hold to Buy. Varonis Systems earned $0.01 in the second quarter, compared to $0.00 in the year-ago quarter. The current stock performance of Varonis Systems shows a 52-week-high of $32.05 and a 52-week-low of $15.61. Moreover, at the end of the la
Wedbush downgraded Chinook Therapeutics from Outperform to Neutral and set a new price target of $42.00
Piper Sandler initiated coverage of Chinook Therapeutics with a rating of Overweight and set a new price target of $41.00
Guggenheim initiated coverage of Chinook Therapeutics with a rating of Buy and set a new price target of $43.00